For example, patisiran (Onpattro) has been approved by the Food and Drug Administration (FDA) in 2018 as the first lipid nanoparticle-based siRNA drug for the treatment of hereditary transthyretin-mediated amyloidosis, which translates such an idea into the clinical practice [46]. This evidence concerns the gene TTR and amyloidosis.